Table 2:
Clinicopathologic characteristics of breast cancers in Lynch Syndrome cohort
| Case | Age | Presentation | Tumor Type |
Grade | Size (cm) | LVI | ER (%) |
PR (%) |
HER2* | Stromal TILS (%) |
PDL-1 (SP142) |
Surgery | Metastasis | TTP (mos.) |
Follow Up (mos.) |
Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 46 | Self-palpated | Ductal | 3 | 3.5 | Yes | 97 | 99 | 2+ | 2% | N/A | TM | Yes | 43 | 171 | AWD |
| 2 | 43 | Self-palpated | Ductal | 3 | 3.2 | Yes | 80 | 90 | 0/1+ | 20% | Negative | TM | Yes | 55 | 67 | DOD |
| 3 | 36 | Palpated on physical exam | Ductal | 3 | 3.5 | Yes | 90 | 95 | 0 | 10% | Negative | TM | Yes | 1 | 47 | AWD |
| 4 | 33 | Screening Mammography | Ductal | 3 | 3.3 | Yes | 99 | 1 | 0 | 25% | Positive | TM | No | N/A | 31 | NED |
| 5 | 47 | Screening Mammography | Lobular | 3 | N/A | N/A | 100 | 95 | 1+ | N/A | N/A | TM | Yes | 108 | 240 | DOD |
| 6 | 64 | Screening Mammography | Ductal | 3 | 1.3 | Yes | 99 | 30 | 0 | 10% | Positive | TM | Yes | 12 | 13 | AWD |
| 7 | 59 | Screening Mammography | Ductal | 2 | N/A | N/A | 0 | 0 | 2+ | 10% | Positive | N/A | Yes | 0 | 11 | AWD |
| 8 | 38 | Self-palpated | Ductal | 3 | 2 | N/A | 99 | 99 | 3+ | 10% | N/A | N/A | Yes | N/A | 15 | AWD |
| 9 | 47 | Self-palpated | Ductal | 2,2 | 1.0,1.0 | Yes | 100 | 70 | 1+ | 10% | Positive | TM | No | N/A | 3 | NED |
| 10 | 63 | Palpated on physical exam | Ductal | 2 | 1 | No | 90 | 2 | 1/2+ | 2% | Negative | BCS | No | N/a | 144 | NED |
| 11 | 74 | Screening Mammography | Lobular | 2 | 1.15 | No | 95 | 90 | 1/2+ | N/A | N/A | TM | No | N/a | 118 | NED |
| 12 | 56 | Screening Mammography | Lobular | 2 | 10 | Suspicious | 90 | 60 | 0 | 1% | Negative | TM | No | N/a | 27 | NED |
| 13 | 42 | Screening Mammography | Ductal | 2 | 1.9 | Yes | 70 | 80 | 0 | 20% | Positive | BCS | Yes | 34 | 36 | AWD |
*
All tumors with 2+ or 1/2 + staining for HER2 IHC were negative for amplification by fluorescent in situ hybridization.
Abbreviations: LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TILs, tumor infiltrating lymphocytes; TTP, time to disease progression; AWD, alive with disease; DOD, died of disease; NED, no evidence of disease; N/A, not available.